MedTrace Logo

A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts

NCT01468636 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-11-02

No results posted yet for this study

Summary

The purpose of this study is to examine the effect of 400 mg of oral zinc gluconate on genital warts. Our hypothesis is that there will be a 10% difference in complete clearance of genital warts in the group randomized to oral plus standard of care compared to those randomized to placebo plus standard of care.

Conditions

  • Genital Warts
  • HPV

Interventions

DRUG

Oral Zinc

200 mg BID of oral zinc gluconate x 8 weeks

DRUG

Placebo

200mg BID x 8 weeks

Sponsors & Collaborators

  • British Columbia Centre for Disease Control

    collaborator OTHER_GOV

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Richard Lester · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468636 on ClinicalTrials.gov